Celltrion (Group)

https://www.celltrion.com

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for Inflectra® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC’s approval for Truxima® and Herzuma®. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Beyond antibody biosimilars, Celltrion is actively engaged in licensing in/out through strategic partnerships with the industry, academia, and research centres to expand its pipelines. Through these partnerships, Celltrion plans to boost the effectiveness of new drug R&D projects and revitalize the bio ecosystems in and outside of Korea. *

	Start	2002-01-01 established
	Today	Celltrion Inc. (KRX: 068270)
	Industry	contract manufacturing (drugs)
	Industry 2	contract manufacturing (biologicals)
	Person	Kee, Woo Sung (Celltrion 201707 CEO)

	Region	Korea, Republic of (town unspecified)
	Country	Korea, Republic of
	Street	Song-do New-city, 13-6, SongDo-Dong, Yeonsu-gu
	City	406-130 Incheon
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2007-11-28)

		* Document for »About Section«: Iksuda Therapeutics Ltd.. (6/7/21). "Press Release: Iksuda Therapeutics Closes $47 Million Financing Round". Newcastle.

		Record changed: 2023-07-10